Fred Thomas, MD
Internal Medicine · Hampton, VANPI 1518958420
Payments from drug & device makers
Across 292 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$737
- Novo Nordisk$612
- GSK$490
- Boehringer Ingelheim$485
- AstraZeneca$440
- Pfizer$392
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,91999%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $737 |
| Novo Nordisk | 38 | $612 |
| GSK | 30 | $490 |
| Boehringer Ingelheim | 26 | $485 |
| AstraZeneca | 27 | $440 |
| Pfizer | 20 | $392 |
| Lilly USA, LLC | 21 | $297 |
| Biohaven Pharmaceuticals, Inc. | 10 | $208 |
| Merck | 13 | $196 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $187 |
| Amgen(2 entities) | 10 | $165 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Amarin Pharma, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Johnson & Johnson | 4 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $51 |
| Novartis | 3 | $48 |
| Abbott | 3 | $44 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Exact Sciences | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Kaleo, Inc. | 1 | $12 |
How this compares
$4,960 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 54 | $55,174 |
| OzempicSemaglutide | 48 | $51,112 |
| TrulicityDulaglutide | 35 | $39,047 |
| JanuviaSitagliptin Phosphate | 44 | $37,046 |
| JardianceEmpagliflozin | 27 | $32,621 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $26,948 |
| EliquisApixaban | 27 | $19,361 |
| FarxigaDapagliflozin Propanediol | 23 | $13,155 |
| MounjaroTirzepatide | 11 | $11,295 |
| EntrestoSacubitril/Valsartan | 12 | $9,815 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,318 |
| LinzessLinaclotide | 13 | $7,198 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,898 |
| Tacrolimus | 12 | $1,741 |
| Atorvastatin Calcium | 180 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $53 | $55,17454 claims |
| Novo NordiskOzempic | $612 | $51,11248 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $297 | $50,34246 claims |
| MerckJanuvia, Janumet | $196 | $44,36457 claims |
| Boehringer IngelheimJardiance | $485 | $32,62127 claims |
| GSKTrelegy Ellipta | $490 | $26,94834 claims |
| PfizerEliquis | $392 | $19,36127 claims |
| AstraZenecaFarxiga | $440 | $13,15523 claims |
| NovartisEntresto | $48 | $9,81512 claims |
| AbbVieLinzess, Synthroid | $737 | $7,54325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Hampton
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.